Patient Preference for Calcipotriene 0.005% Betamethasone Dipropionate 0.064% Foam or Topical Suspension Vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study. J of Skin 2017, 1 (3.1), s26. https://doi.org/10.25251/skin.1.supp.25.